Regional Innovation Ecosystems investment will support a world-class pharmaceutical manufacturing facility
To secure our sovereignty in a more dangerous and uncertain world, Canada needs to build Canadian and buy Canadian. In response, the federal government is investing in domestic manufacturing capacity and prioritizing domestic options in procurement. This is especially important in the pharmaceutical sector, where global supply chain vulnerabilities can affect the availability of essential medicines. In Alberta, leading-edge researchers and experts are stepping up to strengthen Canada's capacity to commercialize novel medicines, reduce drug shortages, secure domestic supply chains, and bolster Canada's biodefence capabilities.
Today, the Honourable Eleanor Olszewski, Minister of Emergency Management and Community Resilience and Minister responsible for Prairies Economic Development Canada (PrairiesCan), announced an additional $50 million in non-repayable funding for the Canadian Critical Drug Initiative (CCDI) through the Regional Innovation Ecosystems program to support Alberta-based researchers to secure critical pharmaceutical production capacity.
This additional investment will support Applied Pharmaceutical Innovation (API), a not‑for‑profit organization that helps innovators commercialize life sciences technologies. In partnership with the University of Alberta, API will use the funding to support construction of the Critical Medicines Production Centre (CMPC). Once complete, the facility will enable the end-to-end large-scale Canadian manufacturing of a variety of pharmaceutical products. This investment will create high-quality jobs, drive economic growth in the Edmonton area, and support Canada's sovereignty by building stronger and more reliable and supply chains.
The CCDI supports the production of critical medicines relied upon in hospitals and pharmacies and, more broadly, contributes to a secure and reliable supply of drugs and biodefence capabilities in support of national defence, aligning with Canada's commitment to rebuild, rearm and reinvest in the Canadian Armed Forces. The research and development of novel drugs by the University of Alberta and industry partners will continue to advance Canada's drug manufacturing and life sciences sector.
This investment is expected to support the growth of at least 60 early-stage life sciences and biomanufacturing companies, the creation of more than 350 high quality jobs, and the training of 175 skilled workers.
